CASI(US:CASI) Jin Rong Jie·2025-08-15 17:12Core Viewpoint - CASI Pharmaceuticals reported significant revenue growth but continued to face net losses, indicating a mixed financial performance as it expands its operations in the oncology sector [1][2]. Financial Performance - As of March 31, 2025, CASI's total revenue reached $6.24 million, reflecting an 83.04% year-over-year increase [1]. - The company's net profit attributable to shareholders was -$10.75 million, which represents a 12.83% decrease compared to the previous year [1]. Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in China [2]. - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi, covering multiple disease areas including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2].